Guideline Video

Guideline Resources

  • Prevention and Control of Influenza in Children, 2026–2027
  • American Academy of Pediatrics
  • August 10, 2026
  • Summary
  • Full-text

Video Transcription

Just published August 10th, 2026, the American Academy of Pediatrics’s newest policy statement on Prevention and Control of Influenza in Children, 2026–2027.

The purpose of this statement is to update recommendations for the use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2026–2027 influenza season.

In today’s rapid update, we’ll just be going over a summary of updates from this statement so for the full policy statement, make sure to check it out on guidelinecentral.com

Let’s get started. 

  • All licensed vaccines available in the United States this season are trivalent.
  • The compositions of influenza vaccines for the 2026–2027 season have been updated.
  • Afluria is no longer available.
  • Recommendations for influenza immunization of immunocompromised hosts have been updated to align with evidence-based recommendations from other groups and professional societies.
  • On January 9th, 2026, the US Food and Drug Administration advised influenza vaccine manufacturers to update prescribing information with the following statement: In two separate postmarketing observational studies, an increased risk of febrile seizures was observed during the first day following vaccination with standard dose trivalent and quadrivalent influenza vaccines in children 6 months through 4 years of age. The magnitude of the attributable risk is low. The package inserts for IIVs were updated.
  • Recommendations for influenza treatment and prophylaxis have been clarified, emphasizing that chemoprophylaxis is not generally indicated for infants younger than 3 months.
  • Baloxavir tablets are available as a generic formulation beginning with the 2026-2027 season.
  • On August 5th, 2026, the FDA approved an mRNA influenza vaccine (mFLUSIVA) for use in adults 50 years and older. The vaccine is not indicated for use in children.

And there you have it. Make sure to check out the full policy statement from the American Academy of Pediatrics and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.